- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
PD-1/PD-L1
亜型選択性的な製品
PD-1/PD-L1製品
- All (40)
- PD-1/PD-L1阻害剤 (11)
- PD-1/PD-L1抗体(29)
- 新製品
| 製品コード | 製品名称 | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|---|
| A2002 | Nivolumab (anti-PD-1) | Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
|
|
| A2004 | Atezolizumab (anti-PD-L1) | Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
|
|
| A2005 | Pembrolizumab (anti-PD-1) | Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. | ||
| S7912 | BMS202 | BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM. | ||
| A2013 | Durvalumab (anti-PD-L1) | Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
.gif)
|
|
| S7911 | BMS-1 | BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. | ||
| S8158 | PD-1/PD-L1 Inhibitor 3 | PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM | ||
| S8275 | Tomivosertib (eFT-508) | Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. | ||
| S8859 | BMS-1166 | BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. | ||
| S8549 | AUNP-12 | AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. | ||
| A2015 | Avelumab (anti-PD-L1) | Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa. |
.gif)
|
|
| A2115 | Anti-mouse PD-L1 (B7-H1)-InVivo | Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80). |
-InVivo.gif)
|
|
| S0094 | SR 0987 | SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. | ||
| A2017 | Spartalizumab (anti-PD-1) | Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. | ||
| E1322 | GS-4224 | GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. | ||
| A2381 | Serplulimab (Anti-PDCD1 / PD-1 / CD279) | Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. | ||
| A2835 | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD. | ||
| A2165New | Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo | |||
| A2156New | Anti-human PD-L1 (B7-H1)-InVivo | Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. | ||
| S8473 | CA-170 (AUPM-170) | CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. | ||
| A2858 | Finotonlimab (Anti-PDCD1 / PD-1 / CD279) | Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD. | ||
| A2022 | Cemiplimab (anti-PD-1) | Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. | ||
| A2613 | Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) | Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD. | ||
| A2882 | Geptanolimab (Anti-PDCD1 / PD-1 / CD279) | Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD. | ||
| A2913 | Iparomlimab (Anti-PDCD1 / PD-1 / CD279) | Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. | ||
| A2122 | Anti-mouse PD-1 (CD279)-InVivo | Anti-mouse PD-1 (CD279)-InVivo (Clone:RMP1-14)reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
-InVivo.gif)
|
|
| A2923 | Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) | Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. | ||
| A2956 | Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) | Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. | ||
| A2998 | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD. | ||
| S9610 | BMS-1001 | BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. | ||
| A2035 | Sintilimab (anti-PD-1) | Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. | ||
| S9863 | INCB086550 | INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. | ||
| A2775 | Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) | Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. | ||
| A2778 | Garivulimab (Anti-B7-H1 / PD-L1 / CD274) | Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD. | ||
| A2780 | Manelimab (Anti-B7-H1 / PD-L1 / CD274) | Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD. | ||
| A2781 | Pacmilimab (Anti-B7-H1 / PD-L1 / CD274) | Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD. | ||
| A2782 | Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) | Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. | ||
| A2783 | Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) | Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD. | ||
| A2016 | Camrelizumab (anti-PD-1) | Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. | ||
| A2811 | Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) | Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD. | ||
| S7912 | BMS202 | BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM. | ||
| S7911 | BMS-1 | BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. | ||
| S8158 | PD-1/PD-L1 Inhibitor 3 | PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM | ||
| S8275 | Tomivosertib (eFT-508) | Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. | ||
| S8859 | BMS-1166 | BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. | ||
| S8549 | AUNP-12 | AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. | ||
| S0094 | SR 0987 | SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. | ||
| E1322 | GS-4224 | GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. | ||
| S8473 | CA-170 (AUPM-170) | CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. | ||
| S9610 | BMS-1001 | BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. | ||
| S9863 | INCB086550 | INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. | ||
| A2002 | Nivolumab (anti-PD-1) | Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
|
|
| A2004 | Atezolizumab (anti-PD-L1) | Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
|
|
| A2005 | Pembrolizumab (anti-PD-1) | Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. | ||
| A2013 | Durvalumab (anti-PD-L1) | Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
.gif)
|
|
| A2015 | Avelumab (anti-PD-L1) | Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa. |
.gif)
|
|
| A2115 | Anti-mouse PD-L1 (B7-H1)-InVivo | Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80). |
-InVivo.gif)
|
|
| A2017 | Spartalizumab (anti-PD-1) | Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. | ||
| A2381 | Serplulimab (Anti-PDCD1 / PD-1 / CD279) | Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. | ||
| A2835 | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD. | ||
| A2165New | Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo | |||
| A2156New | Anti-human PD-L1 (B7-H1)-InVivo | Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. | ||
| A2858 | Finotonlimab (Anti-PDCD1 / PD-1 / CD279) | Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD. | ||
| A2022 | Cemiplimab (anti-PD-1) | Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. | ||
| A2613 | Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) | Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD. | ||
| A2882 | Geptanolimab (Anti-PDCD1 / PD-1 / CD279) | Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD. | ||
| A2913 | Iparomlimab (Anti-PDCD1 / PD-1 / CD279) | Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. | ||
| A2122 | Anti-mouse PD-1 (CD279)-InVivo | Anti-mouse PD-1 (CD279)-InVivo (Clone:RMP1-14)reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
-InVivo.gif)
|
|
| A2923 | Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) | Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. | ||
| A2956 | Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) | Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. | ||
| A2998 | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD. | ||
| A2035 | Sintilimab (anti-PD-1) | Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. | ||
| A2775 | Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) | Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. | ||
| A2778 | Garivulimab (Anti-B7-H1 / PD-L1 / CD274) | Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD. | ||
| A2780 | Manelimab (Anti-B7-H1 / PD-L1 / CD274) | Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD. | ||
| A2781 | Pacmilimab (Anti-B7-H1 / PD-L1 / CD274) | Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD. | ||
| A2782 | Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) | Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. | ||
| A2783 | Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) | Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD. | ||
| A2016 | Camrelizumab (anti-PD-1) | Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. | ||
| A2811 | Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) | Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD. | ||
| A2165New | Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo | |||
| A2156New | Anti-human PD-L1 (B7-H1)-InVivo | Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. |
PD-1/PD-L1阻害剤の選択性比較
Tags: PD-1/PD-L1 inhibition | PD-1/PD-L1 cancer | PD-1/PD-L1 signaling pathway | PD-1/PD-L1 assay | PD-1/PD-L1 inhibitor cancer | PD-1/PD-L1 inhibitor review
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間